A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale.
Mov. Disord.. 2012-09-13; 27(11): 1373-1378
DOI: 10.1002/mds.25133
Read on PubMed
1. Mov Disord. 2012 Sep 15;27(11):1373-8. doi: 10.1002/mds.25133. Epub 2012 Sep 13.
A critique of available scales and presentation of the Non-Human Primate
Dyskinesia Rating Scale.
Fox SH(1), Johnston TH, Li Q, Brotchie J, Bezard E.
Author information:
(1)Toronto Western Research Institute, Toronto Western Hospital, University
Health Network, Toronto, Ontario, Canada.
Levodopa-induced dyskinesia (LID) is a major limitation of long-term management
of Parkinson’s disease. The roadblocks that have hindered the development of new
treatments for levodopa-induced dyskinesia were discussed at a meeting organized
by the Michael J. Fox Foundation for Parkinson’s research (New York, NY, March
2011). Among these, the lack of consensus methodology and clinical applicability
for eliciting and rating LID in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP)-treated monkeys was highlighted as a particular concern. Here we present
an update on the practical use of rating scales for evaluating LID in
MPTP-lesioned primate models of PD, with a focus on macaques, and present
specifics on the Non-Human Primate Dyskinesia Rating Scale.
Copyright © 2012 Movement Disorder Society.
DOI: 10.1002/mds.25133
PMID: 22976821 [Indexed for MEDLINE]